Journal
Cell Reports Medicine
Publication Date
3-19-2024
Volume
5
Issue
3
First Page
101437
Document Type
Open Access Publication
DOI
10.1016/j.xcrm.2024.101437
Rights and Permissions
Yu-Wai-Man P, Carelli V, Newman NJ, Silva MJ, Linden A, Van Stavern G, Szaflik JP, Banik R, Lubiński W, Pemp B, Liao YJ, Subramanian PS, Misiuk-Hojło M, Newman S, Castillo L, Kocięcki J, Levin MH, Muñoz-Negrete FJ, Yagan A, Cherninkova S, Katz D, Meunier A, Votruba M, Korwin M, Dziedziak J, Jurkutė N, Harvey JP, La Morgia C, Priglinger C, Llòria X, Tomasso L, Klopstock T; LEROS Study Group. Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial. Cell Rep Med. 2024 Mar 19;5(3):101437. doi: 10.1016/j.xcrm.2024.101437. Copyright 2024 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Recommended Citation
Yu-Wai-Man, Patrick; Van Stavern, Gregory; and et al., "Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial." Cell Reports Medicine. 5, 3. 101437 (2024).
https://digitalcommons.wustl.edu/oa_4/5210
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
